» Articles » PMID: 7529215

Evaluation of Toxicity and Efficacy of a Combination of Antineoplastic Agents in the Prevention of PVR

Overview
Journal Int Ophthalmol
Specialty Ophthalmology
Date 1994 Jan 1
PMID 7529215
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The retinal toxicity of a combination of antineoplastic drugs in free and liposome-encapsulated form was determined in the rabbit eye. Bleomycin sulfate and 5-fluorouridine were evaluated by clinical observation, electroretinogram, and histological study. Forty-five eyes were injected with combinations of various doses of bleomycin and 5-FUR in free and encapsulated form; 10 eyes served as controls. The nontoxic free dose was found to be 3.5 micrograms bleomycin and 150 micrograms 5-FUR. Liposome encapsulation increased the nontoxic dose to 4.7 micrograms bleomycin and 200 micrograms 5-FUR. Four groups of rabbits in which proliferative vitreoretinopathy had been induced were used for the efficacy study; the control group received an injection of PBS; the second group was injected with a combination of 3.5 micrograms bleomycin and 150 micrograms 5-FUR in free form; the third group was injected with the identical doses in liposome-encapsulated form; and the fourth group received encapsulated bleomycin (4.7 micrograms) and 5-FUR (200 micrograms). The dose used in Group 4 was significantly more effective (P < 0.01) in preventing tractional retinal detachment and marginally more effective (P = 0.054) in preventing neovascularization.

Citing Articles

Biodegradable intraocular therapies for retinal disorders: progress to date.

Kuno N, Fujii S Drugs Aging. 2010; 27(2):117-34.

PMID: 20104938 DOI: 10.2165/11530970-000000000-00000.


Effects of daunorubicin, mitomycin C, azathioprine and cyclosporin A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines.

Garweg J, Wegmann-Burns M, Goldblum D Graefes Arch Clin Exp Ophthalmol. 2005; 244(3):382-9.

PMID: 16091952 DOI: 10.1007/s00417-005-0017-4.


Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study.

Kon C, Asaria R, Occleston N, Khaw P, Aylward G Br J Ophthalmol. 2000; 84(5):506-11.

PMID: 10781515 PMC: 1723478. DOI: 10.1136/bjo.84.5.506.

References
1.
Peyman G, Schulman J . Proliferative vitreoretinopathy and chemotherapeutic agents. Surv Ophthalmol. 1985; 29(6):434-42. DOI: 10.1016/0039-6257(85)90208-5. View

2.
Weiss J, Belkin M . The effect of penicillamine on posttraumatic vitreous proliferation. Am J Ophthalmol. 1981; 92(5):625-7. DOI: 10.1016/s0002-9394(14)74653-7. View

3.
Blumenkranz M, Ophir A, CLAFLIN A, Hajek A . Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 1982; 94(4):458-67. DOI: 10.1016/0002-9394(82)90239-2. View

4.
Wiedemann P, Lemmen K, Schmiedl R, Heimann K . Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am J Ophthalmol. 1987; 104(1):10-4. DOI: 10.1016/0002-9394(87)90286-8. View

5.
Peyman G, Greenberg D, Fishman G, Fiscella R, Thomas A . Evaluation of toxicity of intravitreal antineoplastic drugs. Ophthalmic Surg. 1984; 15(5):411-3. View